Finoriq research workspace

BillionToOne, Inc. (BLLN) Company Overview

BillionToOne, Inc. provides molecular counting platform, which is designed to detect and measure DNA. Review BLLN filings, fundamentals, valuation, and ownership on Finoriq.

Company Snapshot

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

Company

BillionToOne, Inc. (BLLN)

Ticker

BLLN

Market Cap

$5.7B

Latest Price

$124.77

Industry

Medical Devices

Open insider transactions

BillionToOne, Inc. (BLLN) Current Valuation Metrics

Static valuation preview for BillionToOne, Inc. (BLLN). Market data retrieved 2026-07-08. Filing currency USD.

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.